Document is current
Any future updates will be listed below
-
Authors
Duffield, Amy S. https://orcid.org/0000-0003-2018-1964
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
Borowitz, Michael J.
-
Funding
Funding for this research was provided by:
National Cancer Institute, National Institutes of Health (P30 CA008748)
National Cancer Institute, National Institutes of Health (R35 CA197695)
National Cancer Institute, National Institutes of Health (P30 CA021765)
National Cancer Institute, National Institutes of Health (U10 CA180886)
- License Information
-
More Information
Article History
Received: 15 August 2022
Revised: 21 October 2022
Accepted: 27 October 2022
First Online: 24 November 2022
Declarations
: The contents of Tables , , , and are similar to those published in “Arber DA et al. []” because the current review expands on the International Consensus Classification first described in the June 2022 manuscript; however, the contents of the current manuscript have not been copyrighted.
: Authors A.S.D. and M.J.B. declare no competing interests. Author C.G.M. has received speaker (Illumina and Amgen) and consultant (Faze, Beam) honoraria, and receives research funding from AbbVie and Pfizer.
